These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 24333518)
1. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine. Xu D; Wang D; Yang X; Cao M; Yu J; Wang Y Antiviral Res; 2014 Feb; 102():61-9. PubMed ID: 24333518 [TBL] [Abstract][Full Text] [Related]
2. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model. Yan X; Wang D; Liang F; Fu L; Guo C Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698 [TBL] [Abstract][Full Text] [Related]
3. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110 [TBL] [Abstract][Full Text] [Related]
4. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA Virol J; 2015 Sep; 12():140. PubMed ID: 26362430 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Barry EM; Wang J; Wu T; Davis T; Levine MM Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130 [TBL] [Abstract][Full Text] [Related]
6. Surface display of the HPV L1 capsid protein by the autotransporter Shigella IcsA. Xu D; Yang X; Wang D; Yu J; Wang Y J Microbiol; 2014 Jan; 52(1):77-82. PubMed ID: 24390841 [TBL] [Abstract][Full Text] [Related]
7. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055 [TBL] [Abstract][Full Text] [Related]
8. An effective DNA priming-protein boosting approach for the cervical cancer vaccination. Kianmehr Z; Ardestani SK; Soleimanjahi H; Farahmand B; Abdoli A; Khatami M; Akbari K; Fotouhi F Pathog Dis; 2015 Mar; 73(2):1-8. PubMed ID: 25722486 [TBL] [Abstract][Full Text] [Related]
9. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086 [TBL] [Abstract][Full Text] [Related]
10. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642 [TBL] [Abstract][Full Text] [Related]
11. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Yoon SW; Lee TY; Kim SJ; Lee IH; Sung MH; Park JS; Poo H Vaccine; 2012 May; 30(22):3286-94. PubMed ID: 22426329 [TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic. Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614 [TBL] [Abstract][Full Text] [Related]
13. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197 [TBL] [Abstract][Full Text] [Related]
14. Development of a Live Attenuated Bivalent Oral Vaccine Against Shigella sonnei Shigellosis and Typhoid Fever. Wu Y; Chakravarty S; Li M; Wai TT; Hoffman SL; Sim BK J Infect Dis; 2017 Jan; 215(2):259-268. PubMed ID: 27803169 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312 [TBL] [Abstract][Full Text] [Related]
16. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490 [TBL] [Abstract][Full Text] [Related]
17. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania. Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661 [TBL] [Abstract][Full Text] [Related]
18. Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Li W; Liu H; Yang X; Zheng J; Wang Y; Si L Acta Biochim Biophys Sin (Shanghai); 2009 Feb; 41(2):137-45. PubMed ID: 19204831 [TBL] [Abstract][Full Text] [Related]
19. Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine. Berg MG; Adams RJ; Gambhira R; Siracusa MC; Scott AL; Roden RB; Ketner G Clin Vaccine Immunol; 2014 Sep; 21(9):1224-31. PubMed ID: 24990902 [TBL] [Abstract][Full Text] [Related]
20. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine. Hassan SW; Waheed MT; Müller M; Clarke JL; Shinwari ZK; Lössl AG Hum Vaccin Immunother; 2014; 10(10):2975-82. PubMed ID: 25483463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]